Announcement of Resolutions of the 48th Meeting of the 3rd Board of Directors
Guoke Hengtai (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without any false records, misleading statements, or significant omissions.
I. Meeting Information
- The 48th meeting of the 3rd Board of Directors of Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was notified to all directors via email on April 16, 2026.
- The meeting was held on April 27, 2026, in a combination of on-site and communication methods.
- The meeting was convened and presided over by Mr. Liu Bing, the Chairman of the Company. A total of 9 directors were supposed to attend, and all 9 directors were present (with directors Liu Bing and Xiao Wei attending in person, while the other directors attended via communication). Senior management of the Company also attended the meeting.
- The convening, holding, and voting procedures of this Board meeting comply with the relevant provisions of the Company Law of the People's Republic of China (hereinafter referred to as "the Company Law") and other laws, regulations, and the Articles of Association, and are legal and valid.
II. Review of Meeting Resolutions
After careful review and full discussion by the attending directors, the following proposals were approved:
-
Proposal on the 2025 Annual Report and its Summary
After review, the Board believes that the preparation and review procedures of the Company's 2025 Annual Report and its summary comply with the laws, administrative regulations, and the regulations of the China Securities Regulatory Commission. The report content truthfully, accurately, and completely reflects the actual situation of the Company's operations in 2025, with no false records, misleading statements, or significant omissions. The specific content of this proposal can be found in the Company's 2025 Annual Report and Summary disclosed on April 29, 2026, on the designated information disclosure website of the China Securities Regulatory Commission, Giant Tide Information Network (http://www.cninfo.com.cn). The summary was published on the same day in the Securities Times, China Securities Journal, Shanghai Securities Journal, and Securities Daily.
Voting Results: 9 votes in favor, 0 votes against, 0 abstentions. This proposal was approved. The Audit Committee has reviewed this proposal and approved it unanimously. This proposal will also be submitted to the Company's 2025 Annual Shareholders' Meeting for review. -
Proposal on the 2026 Q1 Report
After review, the Board believes that the content of the Company's 2026 Q1 Report is true, accurate, and complete, with no false records, misleading statements, or significant omissions. The specific content of this proposal can be found in the Company's 2026 Q1 Report disclosed on April 29, 2026, on the designated information disclosure website of the China Securities Regulatory Commission.
Voting Results: 9 votes in favor, 0 votes against, 0 abstentions. This proposal was approved. The Audit Committee has reviewed this proposal and approved it unanimously. -
Proposal on the 2025 Annual Board Work Report
The Board has analyzed and summarized the work of the Company for the year 2025. The current independent directors Cheng Xiaoke, Jiang Lian, Chen Xin, and the independent director Zhang Jinxin who left office during the reporting period submitted their Independent Director Annual Work Reports to the Board, which will be presented at the Company's 2025 Annual Shareholders' Meeting. The specific content of this proposal can be found in the "Management Discussion and Analysis" and "Corporate Governance, Environment, and Society" sections of the Company's 2025 Annual Report disclosed on April 29, 2026.
Voting Results: 9 votes in favor, 0 votes against, 0 abstentions. This proposal was approved. This proposal will also be submitted to the Company's 2025 Annual Shareholders' Meeting for review.